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Introduction
I
t is estimated that over 2 billion people have been 
exposed to hepatitis B virus (HBV) worldwide 
(1). About 350 million of the world’s population have 
been infected with HBV (2); for the year 2000 the 
model  estimated  that  620000  patients  died  from 
HBV-related  causes  in  the  world:  6%  from  acute 
hepatitis B (AHB), and 94% from chronic infection-
related hepatocellular carcinoma and cirrhosis (3).
HBV  infection  is  an  important  public  health 
problem  in  the  Middle  East  (4).  Previous  studies 
showed that the prevalence of hepatitis B in Iran ranges 
between 1.3 and 8.69 percent in different regions (5). 
Alavian et al. reported that about 1.5 million people in 
Iran are living with HBV infection, and it is assumed 
that 15% to 40% of them are at risk for developing 
cirrhosis  and/or  hepatocellular  carcinoma  (HCC), 
without intervention (6).
The  goal  of  treatment  for  patients  with 
chronic  hepatitis  B  (CHB)  infection  is  to  prevent 
the  progression  of  liver  disease  to  cirrhosis  and 
hepatocellular  carcinoma  (7).  The  first  aim  of 
antiviral therapy  is the reduction of serum HBV 
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Background and Aims: The treatment of chronic hepatitis B (CHB) is a challenging problem today, and previous study 
has shown that oxidative stress causes the collective pathophysiological conditions of many hepatopathies, so other new 
therapeutic approaches are needed. Hence, in this study the paraclinical and oxidative stress parameters of the efficacy 
of N-acetyl cysteine (NAC) as an antioxidant in the treatment of CHB have been evaluated. 
Methods: In this double-blind placebo-controlled clinical trial study, 43 patients with CHB were enrolled in 2008 in Tehran, 
Iran. The patients were randomly assigned to receive either 1200 mg/day NAC or a placebo for 45 days. Paraclinical tests 
and oxidative stress parameters were measured on experimental day 0 and on day 45.
Results: Liver function tests, i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase 
(ALP) levels were not significantly different in the NAC group and in the placebo group. A reduction in catalase (CAT) activity 
and an increase in glutathione concentration were statistically significant in the NAC group (P < 0.05). 
Conclusions: According to our results, oral NAC is not an effective adjuvant treatment for patients with CHB, but further 
research with a larger population is needed for the evaluation of the effectiveness of NAC in these patients.
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DNA to the lowest possible levels (8) and to improve 
liver  necroinflammation.  This  is  achieved  by  the 
normalization  of  serum  alanine  aminotransferase 
(ALT)  levels,  before  liver  fibrosis  progresses  to  an 
irreversible stage (9).One useful treatment for chronic 
hepatitis is Interferon-alpha (IFN-α), but resistance 
to  this  drug  occurs  frequently  (10).  Also,  IFN-α 
therapy alone, for Chronic Hepatitis C (CHC) is not 
satisfactory, because more than two third of  treated 
patients will not have a sustained response; thus, it 
would be desirable to add some new effective drugs for 
use in combination therapy to improve the response 
rate. (11). 
Also, many side effects such as flu-like symptoms, 
bone marrow suppression and pancreatitis may be 
seen during IFN-α or lamivudine therapy (12, 13).
Oxidative stress results from the extreme production 
of oxidant species in an extracellular environment. A 
major disturbance in the balance of prooxidants and 
antioxidants can lead to cellular damage  (14). Some 
researchers have investigated the relationship between 
oxidative  stress  and  antioxidants  in  hepatitis  virus 
infections and have shown that alternation in redox 
balance characterizes several viral infections and the 
development of virus-induced diseases (15). In many 
liver diseases, inflammation (a source of tumor necrosis 
factor and exogenous reactive oxygen species [ROS]) 
caused by viral infection, increases the speed of the 
killing of liver cells, which may be sensitized by redox 
disturbance  (ROS  and/or  thiol-disulfide)  in  some 
sub-cellular compartments (16). When oxidative stress 
occurs  in  these  patients,  free  radicals  are  controlled 
by many antioxidants, such as glutathione (GSH). In 
addition, experimental and clinical data indicate that 
the production of GSH is reduced in patients with 
chronic viral diseases, like human immunodeficiency 
virus  (HIV)  infection  and  CHC  (11,  17).  Some 
researchers have suggested that NAC, a precursor of 
GSH, has an anti-HBV DNA effect and could inhibit 
the replication of HBV in vitro (17, 18).
Many  studies  have  considered  combination 
therapy with NAC plus IFN-α or lamivudine, for the 
treatment of CHB and CHC, but their results are 
controversial (10, 19, 20); so these findings prompted 
us to carry out a randomized, double-blind, placebo-
controlled  study  to  assess  the  beneficial  effects  of 
combination oral NAC therapy in paraclinical tests 
and oxidative stress parameters in CHB patients.
Materials and Methods
In this study, 43 CHB patients from the Tehran 
Hepatitis Center in Tehran, Iran were consecutively 
chosen in 2008 for this randomized double-blind 
placebo-controlled  trial.  They  had  been  receiving 
CHB  drugs  including  lamivudine,  pegylated 
interferon, and adefovir. The patients were randomly 
assigned to two groups: the NAC group receiving 
1200  mg/day  (Fluimucil,  the  Zambon  Co.)  for 
45 days, and a matching placebo group. Inclusion 
criteria were as follows: a documented diagnosis of 
Hepatitis B, non-participation in any other study, 
and the non-use of any kind of drugs that would 
interact  with  those  used  in  this  study.  Exclusion 
criteria were: the occurrence of any severe side effects 
of NAC, the use of any kind of antioxidant drugs 
and the taking of less than 80% of the medication. 
Tablets  of  both  drug  and  placebo  were  prepared 
by the Zambon Company. Patients and physicians 
were blind to the kind of drug or placebo and so 
was the other research team. Patients enrolled in the 
study were from a clinic in Tehran, Iran. Levels of 
biochemical  parameters,  e.g.  total  bilirubin  (TBil) 
,direct  bilirubin  (DBil),  alanine  aminotransferase 
(ALT),  aspartate  aminotransferase  (AST),  alkaline 
phosphatase (ALP), prothrombine time (PT), GSH, 
catalase  (CAT)  and  superoxide  dismutase  (SOD) 
were monitored in both the NAC and the placebo 
group at experimental day 0 and day 45.
The study was approved by the ethical committee 
of  Baqiyatallah  University  of  Medical  Sciences. 
Written  informed  consent  was  obtained  from  all 
patients before the study was carried out.
Statistical analysis was performed by using SPSS 
software (Statistical Procedures for the Social Sciences 
(version 14.0), Chicago, Illinois, USA). Independent 
sample, paired sample T and Mann-Whitney U tests 
were  performed.  P  values  of  less  than  0.05  were 
considered significant.
Venous blood samples were collected in vacuum 
tubes containing EDTA as the anticoagulant. Plasma 
samples were separated from blood cells and stored 
at -80°C and were used for measuring GSH levels, 
CAT and SOD activities.
GSH  levels  were  determined  using  a  modified 
version of the Tietze method (21). Cellular protein 
was precipitated by the addition of 5% sulfosalisylic 
acid and removed by centrifugation at 3000×g for 15 
min. GSH was assayed in the supernatant as follows: 
to 100 µl of the protein-free cell lysate supernatant 
were added 800 µl of 0.3 mM Na2HPO4 and 100µl 
of 0.04% 5, 5-dithiobis 2-nitrobenzoic acid (DTNB) 
in  0.1%  sodium  citrate.  The  absorbance  of  the 
solution was monitored at 412 nm for 5 min using 
the Beckman UV spectrophotometer. The value for 
each sample was read from the standard curve and 
was expressed in nmol/ml.
CAT  activity  was  determined  following  the 
decomposition  of  H2O2  according  to  the  Cohen Hepatitis Monthly, Spring 2010; 10(2): 95-100
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method  (22).The  reaction  was  started  by  mixing 
H2O2 (6 mM) to the plasma and phosphate buffer 
(50 mM at pH 7.0), and stopped by adding H2SO4 
(6 N) after 3 minutes. Then KMnO4 (0.01 N) was 
added and absorbance measured by means of the 
spectrophotometer at 480 nm. The activity of the 
enzyme was expressed as units per liter.
SOD  activity  was  measured  by  the  inhibition 
of  NADPH  oxidation  (23).  For  assay, TDB  buffer 
(triethanolamine  –  diethanolamine  (0.1M  each)  – 
1.38% HCl buffer at pH 7.4) was added to cuvettes, 
followed by 0.27 mM NADH, 5 mM EDTA, 2.5 mM 
MnCl2 and 0.1 ml of the sample. 2-mercaptoethanol 
(3.75 mM) was added to the mixture and the decrease 
in absorbance was monitored after 5 minutes. One 
unit of activity is defined as the amount of enzyme that 
inhibits the oxidation of NADH by 50% at 25oC.
Results
The mean age of patients was not significantly 
different between the NAC group and the placebo 
group. Out of the 43 patients who enrolled in this 
study, 4 patients, 2 in the NAC group and 2 in the 
placebo group had their participation in the study 
cancelledand  one  patient  in  the  NAC  group  was 
discontinued because of vomiting. Of the remaining 
38  participants,  in  the  NAC  group,  14  patients 
(77%)  were  male,  and  18  patients  (90%)  in  the 
placebo group. The Mean ± standard deviation (SD) 
age of the participants in the NAC and the placebo 
group  was  44.33±13.40,  43.9±13.34,  respectively. 
NAC was tolerated without any serious side effects.
ALT,  AST,  ALP  and  DBil  concentrations 
significantly decreased after administration of NAC 
(P = 0.004, P = 0.024, P = 0.014 and P = 0.01), 
respectively.  These  parameters  had  no  significant 
change  in  the  placebo  group,  except  for  the  AST. 
Also, these parameters were not significantly different 
in the NAC and the placebo group (P > 0.05). Other 
biochemical parameter changes are shown in Table 1.
Changes in SOD activity in both the NAC and 
the placebo group were not significantly different at 
day 45 in comparison to the baseline. Also, there was 
no significant difference between the NAC and the 
placebo group (P > 0.05) (Table1).
The mean CAT activity in the NAC group before 
(14.76 ± 2.45 U/L) and after (8.53±1.43 U/L) the 
study showed a significant decrease (P = 0.02). There 
was no significant difference in CAT activity in the 
placebo group, both before and after the study (P 
Table 1. Oxidative stress parameters and biochemical characteristics at baseline and 45 
days after treatment with NAC and Placebo groups.
Parameters NAC (n=18) P-value Placebo (n=20) P-value
 Age(Mean± SD) year 44.33±13.40 - 43.9±13.34 -
 Sex  Male/Female 14/4 - 18/2 -
 ALT(U/L)
 Base line 76.22 ± 32.7
0.004
91.95± 48.8
P > 0.05
 After 45 days 51.00±22.3 70.50± 60.6
 AST(U/L)
 Base line 57.83±19.4
0.024
67.60 ± 32.7
0.018
 After 45 days 48.06±19.8 48.90± 33.4
 ALP(U/L)
 Base line 237.87±141.7
0.014
211.90 ±86.2
P > 0.05
 After 45 days 134.80±34.3 187.90 ±78.6
 DBil(mg/dl)
 Base line 0.33 ± 0.23
0.01
0.22 ± 0.08
P > 0.05
 After 45 days 0.28 ± 0.19 0.21 ±0.08
 TBil(mg/dl)
 Base line 1.10 ± 0.69
P > 0.05
0.74 ±0.17
P > 0.05
 After 45 days 0.99 ± 0.38 0.81±0.25
 PT(sec)
 Base line 13.48 ± 1.67
P > 0.05
13.59 ± 1.12
P > 0.05
 After 45 days 12.55± 1.16 13.14±0.8
 SOD(U/L)
 Base line 3.39 ± 0.40
P > 0.05
3.87 ± 0.38
P > 0.05
 After 45 days 3.29±0.42 3.84±0.39
 CAT(U/L)
 Base line 14.76 ± 2.45
0.02
12.86 ±1.93
P > 0.05
 After 45 days 8.53±1.43 10.66±1.75
 GSH(nmol/mL)
 Base line 7.5 ± 1.27
0.001
8.48 ± 1.74
P > 0.05
 After 45 days 11.76±2.01 9.96±1.44Hepatitis Monthly, Spring 2010; 10(2): 95-100
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> 0.05). Also, there was no significant difference in 
CAT activity in the NAC and the placebo group (P 
> 0.05) (Table1).
  There  was  a  significant  increase  in  GSH 
concentration in the NAC group, before (7.5 ± 1.27 
nmol/ml),  and  after  (11.76±2.01)  the  study  (P  = 
0.001).There was no significant difference in GSH 
concentration in the placebo group, both before and 
after the study (P > 0.05). There was no significant 
difference in GSH concentration in the NAC and 
the placebo group. (P > 0.05) (Table1).
Discussion
Recently,  combination  therapy  with  vitamin 
E,  or  NAC  and  IFN-α,  has  been  considered  an 
attractive  option  for  hepatitis  patients  (10).  It  is 
assumed  that  during  HCV  infection,  vitamin  E 
and NAC counteract oxidative stress in the hepatic 
microenvironment  caused  by  activated  Kupffer 
cells and infiltrating mononuclear cells  (24). Weiss 
et al. reported that NAC restrains HBV replication 
in  vitro,  but  that  the  mechanism  of  NAC  was 
independent of the intracellular level of ROS. They 
also showed that NAC decreased viral DNA in the 
tissue culture supernatant in vitro at least 50-fold 
within 48 hours. This decrease in viral DNA resulted 
in the disturbance of the virus assembly (18).
Our results showed that TBil and PT decreased in 
the NAC group, but this reduction was not significant 
when compared with the placebo group. Gunduz et al. 
reported that 600 mg/ day oral administration of NAC 
has no effect on a decrease in TBiL and an increase 
in the activity of prothrombine (PTA) (19). Another 
study showed that the injection of NAC can decrease 
the level of serum TBil and increase the PTA  (20). 
In addition, Wang and colleagues assessed that both 
NAC and GSH injection decreased TBil of serum and 
increased PTA in CHB patients, but that NAC was 
more efficient in decreasing TBil than GSH (25).
Our study showed a significant reduction in ALT 
in the NAC group and no significant reduction in 
the  placebo  group;  and  a  significant  reduction  in 
AST in the NAC group and in the placebo group as 
well. Our data are in line with those of another study 
by Gunduz et al. (19). Moreover Grant et al. reported 
serum ALT levels did not differ significantly between 
co-therapy with IFN-α plus NAC, and IFN-α therapy 
alone (26). In agreement with our results, Bernhard et 
al. reported that there was no statistically significant 
difference in ALT and AST between a dose of 1800 
mg/day  of  NAC  and  a  placebo.(11).  However, 
another study could not confirm our observation; 
the authors reported that the serum ALT levels of 
41% of patients were normalized after 6 months of 
IFN-α plus NAC (27).
Similarly to our findings, Look et al. reported no 
significant advantage of an antioxidant plus IFN in 
combination therapy, in terms of response, after 6 
months, compared to IFN monotherapy (24). Also, 
Ideo et al. reported that a combination of IFN-α with 
NAC and vitamin E was not effective in biochemical 
responses rates and clearance of the virus from the 
serum of CHC patients was not observed (28). Our 
data are also in line with those of another study by 
Bernhard and colleagues, who did not find beneficial 
response rates when IFN was combined with NAC, 
in comparison with IFN-α alone (11).
Our  results  showed  that  1200  mg/day  oral 
administration of NAC for 45 days is tolerated by 
patients.  We  did  not  observe  any  serious  adverse 
effects during the 45 days, and these findings are 
in line with those of the study by Weidenbach et 
al., who reported that CHB patients could tolerate 
intravenous  NAC  without  any  side  effects  for  28 
days,  but  NAC  therapy  could  not  have  changed 
HBV-DNA levels significantly (29).
Our  results  demonstrated  that  administration 
of  NAC  reduced  CAT  activity  and  caused  a  rise 
in GSH concentration in the NAC group, but no 
significant reduction of SOD activity was observed 
in this group.
SOD  catalyzes  in  order  to  scavenge  excess 
superoxide anions and convert them to H2O2 and 
other enzymes like CAT and glutathione peroxidase 
scavenge  H2O2  and  convert  it  to  water  (30). 
Investigation has shown that NAC is able to clean 
the cell by scavenging the superoxide anion radicals; 
therefore  a  reduction  of  SOD  and  CAT  activity 
seems  logical  (31).  Researchers  have  reported  that 
erythrocyte  SOD  activity  in  children  with  CHC 
and CHB significantly decreased in comparison to a 
healthy control group (32); in addition, another study 
showed that erythrocyte SOD activity increased in 
acute hepatitis C patients, but decreased in CHC 
patients, and this decrease was reversed when the 
patients were treated with interferon (33). In the Liu 
et al. study, liver SOD activity showed a remarkable 
increase,  when  mice  were  treated  with  NAC  in 
different doses, suggesting that NAC induces SOD 
activity (34). Ozaras et al. showed that NAC elevated 
SOD  activity  in  the  liver  of  rats  given  alcohol 
treatment (35).
Goth et al. reported serum CAT activity in hepatitis 
patients  increased  (36),  and  Bay  et  al.,  in  2002, 
reported CAT activity in CHC patients significantly 
increased  but  decreased  in  CHC  patients  with 
interferon therapy. (32). Other research also showed 
that erythrocyte CAT activity in children with CHB Hepatitis Monthly, Spring 2010; 10(2): 95-100
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and CHC significantly decreased in comparison with 
a healthy control group (33).
One of the key events in hepatocellular damage is 
a decrease in cellular glutathione levels, particularly 
in  the  mitochondrial  ‘slow-turnover’-  GSH  pool. 
GSH  is  one  of  the  key  constituents  of  the  host’s 
antioxidative  capacity.  It  contributes  to  effective 
immune surveillance and to xenobiotic metabolism. 
Since  GSH  itself  is  not  transported  over  bio-
membranes  and  cannot  be  substituted  directly,  its 
abundance might be possible by providing precursors 
such as NAC or GSH esters (27). The results of this 
study showed that GSH concentration increased in 
the NAC group but this increase was not statistically 
significant between the NAC and the placebo group. 
Our results are in accordance with the previous study. 
Bernhard and colleagues showed that 1800 mg/day 
of NAC therapy in CHC patients could increase the 
level of GSH after 12 weeks, but this improvement 
was not significant statistically with the placebo group 
(11). Look et al. found that GSH concentration was 
elevated after administration of NAC in a dose of 1800 
mg/day to chronic hepatitis C patients (24); Arfsten et 
al. reported GSH concentration increased 20% in the 
skin and 50% in the liver after 1200 mg/kg of NAC 
was administered, whereas lung and kidney GSH were 
unaffected in rats (37). Further, another study showed 
that neither interferon nor NAC significantly affected 
GSH  concentration  in  patients  (38).The  author  of 
this article reported in another paper the efficacy of 
NAC in doses of 1200 mg and 1800 mg in the clinical 
improvement of chronic lung disease caused by sulfur 
mustard;  and  also  reported  on  the  parameters  of 
oxidative stress in these patients. The dose of 1200 mg 
in this study is based on the previous study (38-40).
Conclusions
Supplementation  with  NAC  did  not  have 
any  effect  on  paraclinical  tests  and  the  plasma 
concentration of SOD, CAT and glutathione in our 
patients. The administration of NAC in HBV patients 
is based on the hypothesis that the supplementation 
of a prodrug of cysteine, the rate-limiting amino acid 
in glutathione synthesis, will result in an increased 
concentration of antioxidant capacity, so no definite 
conclusions can be drawn from the present study: 
45 days is not enough to draw any conclusion, and 
more time may be needed. 
Acknowledgements
We thank Dr. Mehdi Abouzari, Dr. Saeed Safari, 
Dr. Mehrdad Nooranipour and Dr. Vahid Hoghooghi 
and  Darman  Yab  Darou  Co.  for  their  valuable 
contributions to this work.
Conflict of Interest
Both  the  N-acetylcysteine  (Fluimucil)  and  the 
placebo  tablets  were  provided  by  the  Zambon 
Company. Since all stages of this study were double-
blind,  the  conflict  of  interest  did  not  affect  the 
results.
References
1.  Vahid T, Alavian SM, Kabir A, Kafaee J, Yektaparast B. 
Hepatitis B Prevalence and Risk Factors in Blood Donors in 
Ghazvin, IR. Iran. . Hepat Mon. 2005;5(4):117-22.
2.  Thornley  S,  Bullen  C,  Roberts  M.  Hepatitis  B  in  a  high 
prevalence  New  Zealand  population:  a  mathematical 
model  applied  to  infection  control  policy.  J  Theor  Biol. 
2008;254(3):599-603.
3.  Goldstein  ST,  Zhou  F,  Hadler  SC,  Bell  BP,  Mast  EE, 
Margolis  HS.  A  mathematical  model  to  estimate  global 
hepatitis B disease burden and vaccination impact. Int J 
Epidemiol. 2005;34(6):1329-39.
4.  Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection 
in the Middle East. East Mediterr Health J. 2001;7(6):1034-
45.
5.  Mohammad-Alizadeh  AH,  Ranjbar  M,  Ansari  SH,  et  al. 
[Virologic indices of hepatitis B and its related risk factors 
in population aged 5 years and older in Nahavand in 2002]. 
Pejoohandeh Res J. 2004;8(7):501-6.
6.  Alavian  SM,  Hajarizadeh  B,  Ahmadzad-Asl  M,  Kabir  A, 
Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: 
A Systematic Review. Hepat Mon. 2008;8(4):281-94.
7.  Osborn MK, Lok AS. Antiviral options for the treatment 
of  chronic  hepatitis  B.  J  Antimicrob  Chemother. 
2006;57(6):1030-4.
8.  Keeffe  EB,  Dieterich  DT,  Han  SH,  et  al.  A  treatment 
algorithm for the management of chronic hepatitis B virus 
infection in the United States. Clin Gastroenterol Hepatol. 
2004;2(2):87-106.
9.  Keeffe  EB,  Marcellin  P.  New  and  emerging  treatment 
of  chronic  hepatitis  B.  Clin  Gastroenterol  Hepatol. 
2007;5(3):285-94.
10. Beloqui  O,  Prieto  J,  Suarez  M,  et  al.  N-acetyl  cysteine 
enhances  the  response  to  interferon-alpha  in  chronic 
hepatitis C: a pilot study. J Interferon Res. 1993;13(4):279-
82.
11. Bernhard  MC,  Junker  E,  Hettinger  A,  Lauterburg  BH. 
Time course of total cysteine, glutathione and homocysteine 
in plasma of patients with chronic hepatitis C treated with 
interferon-alpha  with  and  without  supplementation  with 
N-acetylcysteine. J Hepatol. 1998;28(5):751-5.
12. Iorio  R,  Pensati  P,  Botta  S,  et  al.  Side  effects  of  alpha-
interferon therapy and impact on health-related quality of 
life in children with chronic viral hepatitis. Pediatr Infect 
Dis J. 1997;16(10):984-90.
13. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an 
update. J Clin Gastroenterol. 2005;39(8):709-16.
14. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan 
BE. Hepatitis C virus-core and non structural proteins lead Hepatitis Monthly, Spring 2010; 10(2): 95-100
100 Effects of Oral NAC in Chronic Hepatitis B
to different effects on cellular antioxidant defenses. J Med 
Virol. 2005;76(4):489-97.
15. Fraternale A, Paoletti MF, Casabianca A, et al. GSH and 
analogs in antiviral therapy. Mol Aspects Med. 2009;30(1-
2):99-110.
16. Yuan  L,  Kaplowitz  N.  Glutathione  in  liver  diseases  and 
hepatotoxicity. Mol Aspects Med. 2009;30(1-2):29-41.
17. Dikici I, Mehmetoglu I, Dikici N, Bitirgen M, Kurban S. 
Investigation  of  oxidative  stress  and  some  antioxidants 
in patients with acute and chronic viral hepatitis B and 
the  effect  of  interferon-alpha  treatment.  Clin  Biochem. 
2005;38(12):1141-4.
18. Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus 
activity of N-acetyl-L-cysteine (NAC): new aspects of a well-
established drug. Antiviral Res. 1996;32(1):43-53.
19. Gunduz H, Karabay O, Tamer A, Ozaras R, Mert A, Tabak 
OF.  N-acetyl  cysteine  therapy  in  acute  viral  hepatitis. 
World J Gastroenterol. 2003;9(12):2698-700.
20. Shi XF, Guo SH, Wu G, et al. [A multi-center clinical study 
of N-acetylcysteine on chronic hepatitis B]. Zhonghua Gan 
Zang Bing Za Zhi. 2005;13(1):20-3.
21. Tietze F. Enzymic method for quantitative determination 
of  nanogram  amounts  of  total  and  oxidized  glutathione: 
applications to mammalian blood and other tissues. Anal 
Biochem. 1969;27(3):502-22.
22. Cohen G, Dembiec D, Marcus J. Measurement of catalase 
activity in tissue extracts. Anal Biochem. 1970;34:30-8.
23. Paoletti F, Mocali A. Determination of superoxide dismutase 
activity  by  purely  chemical  system  based  on  NAD(P)H 
oxidation. Methods Enzymol. 1990;186:209-20.
24. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant 
combination therapy for chronic hepatitis C--a controlled 
pilot trial. Antiviral Res. 1999;43(2):113-22.
25. Wang N, Shi XF, Guo SH, Zhang DZ, Ren H. [A clinical study of 
N-acetylcysteine treatment in chronic hepatitis B patients]. 
Zhonghua Gan Zang Bing Za Zhi. 2008;16(7):487-9.
26. Grant  PR,  Black  A,  Garcia  N,  Prieto  J,  Garson  JA. 
Combination therapy with interferon-alpha plus N-acetyl 
cysteine for chronic hepatitis C: a placebo controlled double-
blind multicentre study. J Med Virol. 2000;61(4):439-42.
27. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid 
peroxidation and glutathione turnover in chronic anti-HCV 
positive hepatitis. J Hepatol. 1995;22(4):449-56.
28. Ideo  G,  Bellobuono  A,  Tempini  S,  et  al. Antioxidant drugs 
combined  with  alpha-interferon  in  chronic  hepatitis  C  not 
responsive to alpha-interferon alone: a randomized, multicentre 
study. Eur J Gastroenterol Hepatol. 1999;11(11):1203-7.
29. Weidenbach  H,  Orth  M,  Adler  G,  Mertens  T,  Schmid 
RM.  Treatment  of  chronic  hepatitis  B  with  high-dose 
intravenous  N-acetyl-L-cysteine.  Hepatogastroenterology. 
2003;50(54):2105-8.
30. Jafari  M.  Dose-  and  time-dependent  effects  of  sulfur 
mustard on antioxidant system in liver and brain of rat. 
Toxicology. 2007;231(1):30-9.
31. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant 
action  of  N-acetylcysteine:  its  reaction  with  hydrogen 
peroxide,  hydroxyl  radical,  superoxide,  and  hypochlorous 
acid. Free Radic Biol Med. 1989;6(6):593-7.
32. Karabulut  AB,  Sonmez  E,  Bayindir  Y,  Gozukara  E.  A 
comparison  of  erythrocyte  superoxide  dismutase  and 
catalase activity in patients with hepatitis C infection. Turk 
J Med Sci. 2002;32(4):313-6.
33.	Chrobot	 AM,	 Szaflarska-Szczepanik	 A,	 Drewa	 G.	
Antioxidant defense in children with chronic viral hepatitis 
B and C. Med Sci Monit. 2000;6(4):713-8.
34. Liu Y, Zhang H, Zhang L, et al. Antioxidant N-acetylcysteine 
attenuates the acute liver injury caused by X-ray in mice. 
Eur J Pharmacol. 2007;575(1-3):142-8.
35. Ozaras R, Tahan V, Aydin S, Uzun H, Kaya S, Senturk 
H.  N-acetylcysteine  attenuates  alcohol-induced  oxidative 
stress in the rat. World J Gastroenterol. 2003;9(1):125-8.
36. Goth  L,  Meszaros  I,  Nemeth  H.  Serum  catalase  enzyme 
activity in liver diseases. Acta Biol Hung. 1987;38(2):287-
90.
37. Arfsten  DP,  Johnson  EW,  Wilfong  ER,  Jung  AE,  Bobb 
AJ.  Distribution  of  radio-labeled  N-Acetyl-L-Cysteine 
in  Sprague-Dawley  rats  and  its  effect  on  glutathione 
metabolism  following  single  and  repeat  dosing  by  oral 
gavage. Cutan Ocul Toxicol. 2007;26(2):113-34.
38. Shohrati M, Ghanei M, Shamspour N, Jafari M. Activity 
and  function  in  lung  injuries  due  to  sulphur  mustard. 
Biomarkers. 2008;13(7):728-33.
39. Shohrati M, Aslani J, Eshraghi M, Alaedini F, Ghanei M. 
Therapeutics  effect  of  N-acetyl  cysteine  on  mustard  gas 
exposed  patients:  evaluating  clinical  aspect  in  patients 
with  impaired  pulmonary  function  test.  Respir  Med. 
2008;102(3):443-8.
40. Ghanei M, Shohrati M, Jafari M, Ghaderi S, Alaeddini F, 
Aslani J. N-acetylcysteine improves the clinical conditions 
of mustard gas-exposed patients with normal pulmonary 
function test. Basic Clin Pharmacol Toxicol. 2008;103(5):428-
32.